CORRECTION article

Front. Immunol., 05 December 2023

Sec. Cancer Immunity and Immunotherapy

Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1345513

Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

  • 1. Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan

  • 2. Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan

  • 3. Showa University Research Administration Center, Showa University, Tokyo, Japan

  • 4. Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan

  • 5. Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan

  • 6. Pharmacological Research Center, Showa University, Tokyo, Japan

In the published article, there was an error in the legend for Figure 2 and Figure 3 as published. Figure 2B and Figure 3B; Hazard ratios of overall death, and Figure 3 legend; B; disease progression. The corrected legend appears below.

Figure 2

Figure 3

Figure 2B and Figure 3B; Hazard ratios of disease progression, and Figure 3 legend; B; disease progression.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

soluble PD-L1, advanced non-small cell lung cancer, PD-1 inhibitors, individual patient data meta-analysis, biomarker

Citation

Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T and Wada S (2023) Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis. Front. Immunol. 14:1345513. doi: 10.3389/fimmu.2023.1345513

Received

27 November 2023

Accepted

29 November 2023

Published

05 December 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Copyright

*Correspondence: Satoshi Wada,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics